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Abstract
Background To evaluate the two-year efficacy of photo-
dynamic therapy with Visudyne (PDT) in neovascular age-
related macular degeneration (AMD) eyes with chorioretinal
anastomosis (CRA).
Methods A non-randomized, institutional, prospective
study, of 28 consecutive eyes of 23 patients, with CRA,
treated with PDT. Masked best corrected visual acuity (VA)
and angiographic features at baseline and during the period
of two years were evaluated.
Results Twenty eight eyes completed one year and 19 eyes
completed two years of follow-up. The number of treat-
ments was 3 in the first year, and 0.8 in the second year. A
VA loss < 3 lines occurred in 53% of the eyes, at two years.
Treated eyes lost 0.5 lines in the first year and 2.4 lines in
the second (p<0,01). Recurrence with additional significant
VA loss occurred in four eyes (21%) during the second
year. Fourteen eyes (74%) showed no fluorescein leakage at
two years.
Conclusion AMD eyes with chorioretinal anastomosis can
benefit from PDT with Verteporfin at two years. However,
during the second year significant additional VA loss occurs
mainly due to recurrence. New modalities of treatment are
necessary to achieve VA improvement in CRA eyes.
Keywords AMD . Chorioretinal anastomoses . PDT.
Photodynamic therapy . RAL-retinal anastomosis
to the lesion . RAP. Visudyne
Introduction
Chorioretinal anastomosis, a phenotype of exudative age-
related macular degeneration (AMD), may represent 5–28%
of AMD exudative cases [1, 5, 8]. Different names were
proposed including retinal angiomatous proliferation (RAP)
[22], deep retinal vascular anomalous complex [7, 11] and
more recently retinal anastomosis to the lesion (RAL) [17].
Treatment options including thermal laser photocoagulation
[8], transpupillary thermotherapy [10] and surgery [2] have
been tried without success. Photodynamic therapy with
Verteporfin (PDT) [3, 15] and combined therapies (PDT
plus intravitreous triamcinolone) [6, 18] have shown a
higher efficacy at 12 months. The 2-year follow-up of CRA
eyes treated with PDT is already unknown.
The purpose of this study is to evaluate, in a non-
randomized, interventional, institutional, prospective study,
the two-year efficacy of PDT with verteporfin in eyes with
neovascular AMD and CRA.
Patients and methods
A prospective, institutional, non-randomized, non-con-
trolled study was performed in 28 consecutive eyes, of 23
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patients with exudative AMD and CRA, observed after
January 2000 and treated with PDT with Verteporfin.
Patients and methods were previously described [15].
PDT treatments were performed within 3-month intervals,
using the standard protocol of TAP and VIP trials [20, 21]
but also including eyes with serous pigment epithelium
detachment greater than 50% of the lesion. Retreatments
were applied if fluorescein angiography showed any
leakage from the neovascular lesion, causing VA decrease.
All patients had 50 years or more of age at the time of
diagnosis, and presented signs of AMD. Only patients with
12 or more months of follow-up were considered for the
study.
Stereo colour, red-free fundus photographs and stereo
fluorescein and digital ICG angiograms obtained with the
Topcon ImageNet system were reviewed by two indepen-
dent reviewers (R.M.S., J.R.F.A.) and any disagreement
was resolved by a third reviewer (J.G.C.V.). The criteria for
diagnosis were previously described [15] and were based
on Slakter’s [16] descriptions. Briefly, we considered the
possibility that biomicroscopic and red-free findings sug-
gested the presence of CRA when intraretinal or preretinal
small haemorrhages and intraretinal edema (cystoid or not)
were present. Fluorescein angiography (FA) and indocya-
nine-green video-angiography (ICG) were highly sugges-
tive of CRA when early and/or late focal hot spots were
present. Definitive CRA was only assumed when positive
signs were identified on biomicroscopy and red-free
photography and with at least one of the two angiographic
techniques. Lesions, at the time of diagnosis were
≤5400 μm in size (greatest linear dimension) in all cases.
Visual acuity (VA) was tested by a masked observer
using the ETDRS chart and the best-corrected VA was
obtained. The neovascular lesions were classified in
predominantly classic, minimally classic, and occult with
no classic according to MPS, TAP and VIP protocols [12,
20, 21]. The stages of CRA were identified according to
Yannuzzi criteria [22]: stage I involving proliferation of
intraretinal capillaries originating from the deep retinal
complex (intraretinal neovascularization); stage II charac-
terized by the growth of retinal vessels into the subretinal
space (subretinal neovascularization) with or without serous
pigment epithelial detachment, and stage III when clinical
and angiographic examinations clearly demonstrated the
presence of choroidal neovascularization.
All the FA and ICG images were analyzed and classified
according to the presence or absence of leakage and by the
resolution of exudation with predominance of atrophy or
fibrosis. Resolution with fibrosis was considered when
≥50% of the lesion was fibrotic; atrophy was considered
when ≥50% of the lesion was atrophic.
The evolution of VA was classified in two groups: 1-VA
improvement (moderate: <3 lines, and significant: ≥3 lines);
and VA decrease (moderate: <3 lines, severe: ≥3<6 lines,
and very severe: ≥6 lines). Optical Coherence Tomography
(OCT) was performed in some patients, in a non regular
basis, and only after 2003.
We considered to exist recurrence when subfoveal or
juxta-foveal FA and/or ICG leakage with VA loss was
observed after two periods of three months without
treatment (a period greater than 6 months without treat-
ment). The reason for choosing such an interval is related to
the necessity of clearly differentiate persistence and
recurrence, giving enough time for resolution of residual
leakage. The eyes with incomplete resolution of leakage at
the three months visit (area of leakage inferior to 50% of
the lesion and not affecting VA) were not treated and were
considered to have persistence. If 3 months later the leak-
age area was greater than 50% of the lesion (or affecting
VA) this was not considered a recurrence but a persistence
and PDT was performed. The lesion was only considered
cured after six months without need for treatment. Any
necessity of treatment after this period was classified as
recurrence.
Extra-foveal leakage with no VA loss was not treated
and was not considered as recurrence.
To test the statistical differences between groups (mean
differences) Mann-Whitney test (for 2 groups) or Kruskall-
Wallis test (for more than 2 independent groups) were
chosen. For statistical differences among and between visits
the Friedman and Wilcoxon tests were respectively used.
For correlations between the different parameters the Chi-
Square test (for categorical parameters), the Pearson and
Spearman correlation coefficients (for continuous variables)
were performed.
The study was approved by an internal review commit-
tee and conducted in accordance to the ethical standards
laid down in the 1964 Declaration of Helsinki. Each patient
signed an informed consent form after being completely
instructed.
Results
Twenty eight eyes of 23 patients, 19 women and 4 men,
were treated with PDT with Visudyne. Mean age of the
patients was 77.3 years (SD: 4.0, var: 70–86) and mean
follow-up period was 30.8 months (range 12–66). All the
eyes were observed at 12 months and 19 eyes completed
the 2-year follow-up (Tables 1, 2). Nine eyes (8 patients)
did not complete the 2-year follow-up: five patients missed
the follow-up (cases 7,10,17,19,23,24), one patient died
(case 15), one was treated with combined therapy at month
12 (case 27) and one had only 21 months follow-up at the
time of final evaluation (case 4).
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Vision outcomes
The efficacy of PDT decreased during the second year of
follow-up (Tables 2, 3). Treated eyes lost 0.5 lines in the
first year and 2.4 lines in the second (p=0.019). There was
a significant visual acuity decline between baseline and
24th month visit (p=0.002). The number of eyes with
reading vision or with VA loss inferior to 3 lines decreased
in the second year whereas the number of eyes with legal
blindness and very severe VA loss increased (Table 3).
Treatments administered
Twenty eight eyes completed 12 months of follow-up and
performed a mean number of 3 PDT sessions (SD:1.1;
Var:1–4) (Table 2). Nineteen eyes completed 24 months of
follow-up and performed a mean number of 3.8 PDT
sessions during the two-year follow-up (SD: 1.7; var: 1–7).
The mean number of treatments decreased from 3 in the
first year to 0.8 in the second year (Table 2) (Fig. 1).
Angiographic evaluation
No leakage documented on FA and/or ICG was observed in
46% and 74% of the eyes at years 1 and 2, respectively.
Recurrences occurred in 5 eyes (26%) during the 2-year
follow-up: one case in the first year (3,6%) and 4 in the
second year (25%). Four additional cases occurred after two
years (Figs. 2, 3). The 4 eyes with recurrence during the
second year [2, 6, 18, 20] presented a mean VA loss of 5
lines related to the recurrence, (var: 2–9 lines).
The mean interval between the last treatment and the
recurrence was 12 months for the recurrences up to
24 months of follow-up, and 16 months (SD:6,1; var: 9–
29 months) for all 9 eyes with recurrence. Two cases
showed two recurrences during the follow-up (cases 20
and 28).
At the final observation the eyes with recurrence had
lost more lines of VA (5,2 lines,SD:2,4; var:−2 to−7
lines, Vs 0,6 lines, SD: 3,8; var:+4 to−12; p=0,01), had
a longer follow-up (p<0.01), and received more treat-
ments (p=0.013) than eyes without recurrence.
There was no difference between eyes with and without
recurrence regarding the lesion size, presence of serous
PED, mean initial or final VA.
Serous PED Ten eyes (36%) presented serous PED greater
than 50% of the lesion, at the initial visit (Fig. 1). PED rip
occurred only in one case. Only two of these eyes had
leakage at the final visit. No difference was found between
Table 3 VA results at one and two years and at the final evaluation
Baseline N=28 12 Months N=28 24 Months N=19 Final Observation. N=28
Mean visual acuity (logMar) 0.92 0.91 1.12 1.13
Loss < 3 lines — 79 % n=22 53 % n=10 57 % n=16
VA equal or better — 57 % n=16 42 % n=8 43 % n=12
Moderate VA loss — 21 % n=6 11 % n=2 14 % n=4
Severe VA loss — 18 % n=5 26 % n=5 21 % n=6
Very severe VA loss — 4 % n=1 21 % n=4 21 % n=6
AV ≥ 20/63 36 % n=10 32 % n=9 21 % n=4 18 % n=5
AV ≤ 20/200 36 % n=10 39 % n=11 47 % n=9 68 % n=19
N Minimum Maximum Mean SD
age 28 70 86 77.3 4.1
Follow-up 28 12 66 30.8 15.7
Initial lesion size (micra) 28 1700 5400 4000 1023
Initial VA (logMar) 28 0.1 1.6 0.92 1.0
VA at year 1 (logMar) 28 0.3 1.3 1.12 0.8
Lines variation year 1 28 −7 4 −.50 2.7
N° treat. Up to 12M 28 1 4 3 1.1
VA at year 2 (logMar) 19 0.4 1.5 1.03 0.9
Lines variation up to 24M 19 −12 4 −2.4 4.3
N° treat. Up to 24M 19 1 7 3.8 2
N° treat. during 2° year 19 0 3 0.8 1.0
Final VA (logMar) 28 0.3 1.5 1.13 0.89
Lines variation final VA 28 −12 4 −2.2 3.9
N° treat. Final visit 28 1 12 4.3 2.8
Table 2 Age, lesion size, visual
acuity evolution and number
of treatments
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cases with and without serous PED regarding lines of VA
lost and number of treatments, at 24 months.
Stage of the lesion According to Yannuzzi’s classification
8 eyes were at stage one, 16 at stage two and 4 at stage
three (Table 1). The lesions of stage 1 were significantly
smaller than those of stage 2 (p<0.05), but not than those of
stage 3 (p>0.05). The number of treatments was 3.3
(sd:3.3); 4 (sd:1.6) and 7.5 (sd:3.9) for stages 1, 2 and 3
respectively (p=0.03). The eyes at stage 2, but not the eyes
at stage one or three, showed a significant VA loss at 12
and 24 months (p=0.02).
Lesion size Lesion size correlated with initial VA (R=
0.456. p=0,01). The eyes with a lesion size greater than 4
MPS disc area at baseline suffered a significant VA loss
between 12 and 24 months (p=0.03).
FA lesion classification and outcomes Twenty seven eyes
had occult CNV-21 with fibrovascular pigment epitheli-
Fig. 1 a Case 3. Baseline. VA
LE: 20/160. Fluorescein angi-
ography (a and b) and ICG
showing CRA with serous PED.
A hot spot can be observed on
FA and ICG. b Case 3 at
24 months and after 7 PDT
sessions. The lesion still has
leakage (FA, images a and b). A
ring of lipid exudates is ob-
served on red-free images (c).
OCT shows flattening of PED
and cystoid edema
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um detachment and 6 with late leakage from undeter-
mined source -, one eye had a minimally classic CNV
(Table 1).
At the final observation 9 eyes (32%) showed resolution
of the lesion with chorioretinal atrophy and no leakage or
fibrosis. Fourteen eyes (50%) showed evolution to fibrosis,
and leakage was present in five (36%) of them. There was
no difference between the two groups regarding initial VA,
final VA, size of the lesion, number of treatments, or vision
loss (p>0.05).
Fig. 2 a Case 27. CRA at
baseline. Superficial retinal
haemorrhages are better visual-
ized on red_free pictures. Dif-
fuse oedema and a small PED
may be observed on FA (a and b
pictures). ICG shows a barely
defined hot spot. b Case 27 at
after 1PDT session (Picture a
and b). Seven months later
recurrence is observed (c and d)
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Fig. 3 a Case 23. Baseline. Red-
free picture (a) with superficial
retinal haemorrhages. FA shows
a focal hot spot at 43 seconds. A
focal hot spot is also observed
in ICG early and late phases.
b Case 23. At six months and
after 2 PDT sessions. Red-free
picture (a): No retinal
haemorrhages are visualized.
FA and ICG show resolution
of exudation
Graefe’s Arch Clin Exp Ophthalmol (2007) 245:1131–1139 1137
Discussion
Our study evaluates the two-year efficacy of PDT in AMD
eyes with CRA. We have found a significant VA decline
between baseline and the 2-year visit. The more severe VA
prognosis, during the second year, was related to the
presence of recurrences. Apparently CRA has a particular
outcome different from other eyes with choroidal neo-
vascularization. Recurrences are frequent and associated
with significant VA loss. The four cases with recurrence
during the second year were responsible for 47% of the
lines lost in the same period. The rate of recurrences
increased with longer follow-up. Possible reasons for recur-
rences may include, according to Criswell [4]: 1-relatively
higher retinal blood flow rate in the proximal retina; 2-sus-
tained arterial pressure of retinal blood vessels resulting in
distension of both retinal and anastomotic trunks, after PDT
occlusion; 3-PDT, although effective in occluding smaller
diameter new vessels of choroidal origin (up to approxi-
mately 5 μm diameter), may not be effective in blocking
larger diameter blood vessels (5 μm diameter and larger).
CRA is a particular form of neovascular AMD. It has two
foci of neovascularisation, one at the retinal level and the
other at the choroidal level. We may speculate that despite
the apparent occlusion of CRA with Visudyne, a connexion
between retinal circulation and CRA may persist. Viable
anastomotic vessels could contribute to the subsequent
long-term revascularization of treated CRA and to contin-
ued angiogenesis.
The efficacy of PDT in eyes with CRA has been
questioned by some authors [4, 9]. No data are available
from randomized, multicentre clinical trials like TAP, VIP
or VISION because ICG was not used and CRA was not
identified as clinical entity. Patients with CRA were
included and classified as occult, minimally classic or
predominantly classic lesions. A retrospective analysis of
TAP and VIP studies has shown that the presence of CRA
(also called “associated retinal anastomosis to the lesion-
RAL”) should not influence Verteporfin treatment recom-
mendations at 2 years [17]. Treated eyes compared with
placebo eyes, had a reduced risk of losing 3 or more lines
of visual acuity, a reduced risk of having visual acuity
worse than 20/200, and had a reduced mean visual acuity
loss from baseline [17]. Limitations of this analysis are
related to two facts: first, it was retrospective and second,
ICG was not used for the diagnosis. Accepting these
limitations we may consider that the results are, likewise
in our work, in favour of benefit of treating CRAwith PDT.
We know the natural history of CRA at one year [15] but
not at two years. PDT has shown benefit at one year when
compared with natural evolution. Sixty nine percent of the
untreated eyes loose more than three lines at one year, [15],
compared to 21% of the eyes treated with PDT. Natural
evolution of CRA has not shown cases with VA improve-
ment at 12 months [14], compared to 18% of cases in the
PDT group.
A comparison at two years can be done with VIP trial
results [21] considering that our membranes were occult in
96% of the cases: 45% of treated eyes in the VIP study lost
less than 3 lines at two years, comparing with 53% in our
study. However this comparison needs to be cautiously
looked at since our study has limitations such as being an
open, interventional, institutional and nonrandomized study
with a relatively small sample.
The importance of classifying lesions in stage 1, 2 and 3
is an interesting issue. Stages 2 and 3 are assumed to have a
more severe prognosis without treatment. We have found
no difference between stages 1, 2 and 3 regarding initial
VA, VA at 12 and 24 months. The eyes in stage 2 showed a
significant VA loss at 24 months. The reduced number of
eyes with 24 months of follow-up in stage 1 or 3 prevents
us to further conclude about the importance of Yannuzzi’s
stages for VA outcome in eyes treated with PDT.
The presence of serous PED greater than 50% of the
lesion is assumed to be a sign of bad prognosis and a
potential counterindication for PDT [3, 14]. These lesions
were not included in TAP and VIP studies [19–21]. We
have treated 10 eyes with CRA and serous PED greater
than 50% of the lesion. The lesions with serous PED were
larger (Student t test, p<0.05) and we found no differences
between eyes with and without serous PED regarding lines
of VA lost and number of treatments at two years (p>0.05,
student t test). A PED rip occurred in one case (17%). In
our study serous PED seems not to change the VA
prognosis of treated lesions. However, these conclusions
are limited by the reduced number of eyes with serous PED
at 2 years of follow-up (six cases).
Treating CRA with PDT may stabilize vision in a high
percentage of eyes but the number of eyes with VA
improvement is small. New treatment modalities using
single or combined therapies including antiangiogenic
agents or PDT with intravitreous triamcinolone (IVT) may
probably offer more benefits [13, 18]. At the moment there
are no available data regarding the efficacy of antiangio-
genic or angiostatic agents in the treatment of CRA.
However, combining PDT with IVT seems to be more
effective than PDT alone at 12 months [6]. Complete
resolution of the angiographic leakage has been achieved in
89% of eyes, visual acuity improvement in 37% and VA
stabilization in 52% of eyes. Thirty percent of the cases
presented recurrent leakage after 3 to 11 months [6]. These
results are clearly better that PDT alone at one year. The
rate of recurrences is higher than in our study. This may be
due to two reasons: one, more cases may have been closed
with combined therapy during the first year, and second,
Freund and col., considered any retreatment as a recurrence,
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whereas we considered recurrences only after an interval
greater than six months had elapsed.
In conclusion, eyes with CRA may benefit with PDT up
to two years of follow-up. However, during the second year
a significant VA decline may occur mainly due to
recurrence. New treatment modalities are necessary to
achieve VA improvement in CRA eyes.
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